Phase 2 Dose-Escalating, P-C, D-B, Parallel Group Study in HIV Treatment-Experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days (PART B).

Trial Profile

Phase 2 Dose-Escalating, P-C, D-B, Parallel Group Study in HIV Treatment-Experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days (PART B).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2010

At a glance

  • Drugs Bevirimat (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors Panacos Pharmaceuticals
  • Most Recent Events

    • 22 Jan 2010 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Additional lead trial centre (Myriad Pharmaceuticals) identified as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Phase IIb data reported at ICAAC/IDSA 2008, according to a Panacos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top